Perennial biotech investor and backer Takeda has signed its latest collaboration with Nektar Therapeutics that will see the pair work on combo cancer…

Amgen and UCB's romosozumab trounced a comparator drug in a trial in osteoporosis, but there's a big catch: The therapy seems to cause side effects…

Celgene has posted some new late-stage data from its second pivotal test in multiple sclerosis for its $7.2 billion oral candidate ozanimod, showing it could…

Shire and drug partner Xenetic have released new data for their collaborative bleeding disorder drug SHP656, and the news isn’t good.

La Jolla Pharmaceutical has posted a full look at data from a phase 3 trial of its vasodilatory shock candidate LJPC-501.

AB Science says its drug candidate masitinib has slowed down progression in a late-stage trial, but its checkered development history means the reaction is…

Roche has published early clinical data on its bispecific antibody in heavily pretreated patients with metastatic colorectal cancer.

Shire's dominant position in the hereditary angioedema market just firmed up with stellar data for its new candidate lanadelumab.

President Donald Trump is considering switching up his attack on U.S. health research budgets by capping how much the NIH can spend on indirect costs.

R&D